Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial

Mayo Clinic Proceedings

Volumn 74, Issue 11, 1999, Pages 1095-1105

  Bensen, William G ^a,b,c,d,e   Fiechtner, Justus J ^a   Mcmillen, James I ^a   Zhao, William W ^a   Yu, Shawn S ^a   Woods, Emmett M ^a   Hubbard, Richard C ^a   Isakson, Peter C ^a   Verburg, Kenneth M ^a   Steven Geis, G ^a,b  

^a ST JOSEPH S HOSPITAL   (Canada)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c Rheumatology and Clin Res Center   (United States)

^d PFIZER INC   (United States)

^e NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOARTHRITIS; RANDOMIZED CONTROLLED TRIAL;

EID: 0033507971     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/74.11.1095     Document Type: Article

References (45)

1. Vane JR, Bolting RM. Biological properties of cyclooxygenase products. In: Cunningham FM, ed. Lipid Mediators. London, England: Academic Press Ltd; 1994:61-97.
2. Abramson SR, Weissmann G. The mechanisms of action of nonsteroidal antiinflammatory drugs. Arthritis Rheum. 1989;32:l-9.
3. Smith WL, Dewitt DL. Prostaglandin endoperoxide H synthases-1 and-2.AdvImmunol. 1996;62:167-215.
4. Kujubu DA, Herschman HR. Dexamethasone inhibits mitogen induction of the TIS 10 prostaglandin synthase/cyclooxygenase gene. JBiolChem. 1992;267:7991-7994.
5. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Nat! Acad Sei USA. 1991:88:2692-2696.
6. O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxgenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett. 1993;330:156-160.
7. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. / Rheumatol. 1997;24(suppl 49): 15-19.
8. Kargman S, Charleson S, Cartwright M, et al. Characterization of prostaglandin G/H synthase 1 and 2 in rat, monkey, and hu-man gastrointestinal tracts. Gastroenterology. 1996:111:445-454.
9. Seibert K, Zhang Y, Leahy K, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sei USA. 1994;91:12013-12017.
10. Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. / Biol Chem. 1990:265:1673716740.
11. Crofford LJ, Wilder RL, Ristimäki AP, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues: effects of interleukin-l, phorbol ester, and corticosteroids. ./ Clin Invest. 1994:93:1095-1101.
12. DuBois RN, Awad J, Morrow J, Roberts LJ II, Bishop PR. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-alpha and phorbol ester. J Clin Invest. 1994:93:493-498.
13. Gierse JK, Hauser SD, Creely DP, et al. Expression and selective inhibition of the constitutive and inducible forms of human cyclooxygenase. BiochemJ. 1995:305:479-484.
14. Laneuville O, Breuer DK, Dewitt DL, Hla T, Funk CD, Smith WL. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J PharmacolExp Ther. 1994;271:927-934.
15. Masferrer JL, Zweifel BS, Manning PT, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sei USA. 1994:91:3228-3232.
16. Anderson GD, Hauser SD, McGarity KL, Bremer ME, Isakson PC, Gregory SA. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest. 1996;97:2672-2679.
17. Zhang Y, Shaffer A, Portanova J, Seibert K, Isakson PC. Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E, production. J Pharmacol Exp Ther. 1997:283:1069-1075.
18. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, et al. Synthesis and biological evaluation of the 1,5diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluromethyl)-lH-pyrazoll-yl]benzenesulfonamide (SC-58635, celecoxib). J Med Chem. 1997:40:1347-1365.
19. Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum. 1998:41:15911602.
20. Altman R, Asch E, Bloch G, et al, Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum. 1986;29:1039-1049.
21. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA. 1949; 140:659-662.
22. Lequesne MG, Mery C, Samson M, Gerard P. Indexes of severity for osteoarthritis of the hip and knee: validation-value in comparison with other assessment tests [published corrections appear in Scand J Rheumata! Suppl. 1988;73:1 and Scand J Rheumatol. 1988;17:following 241]. Scand J Rheumatol Suppl. 1987;65:8589.
23. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. JRheumatol. 1988; 15:1833-1840.
24. Cooperating Clinics Committee of the American Rheumatism Association. A seven day variability study of 499 patients with peripheral rheumatoid arthritis. Arthritis Rheum. 1965;8:302334.
25. Langley GB, Sheppeard H. Problems associated with pain measurement in arthritis: comparison of visual analogue and verbal rating scales. Clin Exp Rheumatol. 1984:2:231-234.
26. American Pain Society Quality of Care Committee. Quality improvement guidelines for the treatment of acute pain and cancer pain. JAMA. I995;274:1874-1880.
27. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75:800-802.
28. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995; 123:241-249.
29. Simon LS, Weaver AL, Graham, DY, et al. The anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized, controlled trial. JAMA. In press.
30. Emery P, Zeidler H, Kvein TK, et al. Randomised double-blind comparison of celecoxib versus diclofenac in long-term management of rheumatoid arthritis. Lancet. In press.
31. Goldstein JL, Agrawal NM, Silverstein F, et al. Celecoxib is associated with a significantly lower incidence of clinically significant upper gastrointestinal (UGI) events in osteoarthritis (OA) and rheumatoid arthritis (RA) patients as compared to NSAIDs [abstract]. Gastroenterohgy. 1999;! 16(suppl):A174.
32. Siegle I, Klein T, Backman JT, Saal JG, Nusing RM, Fritz P. Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase in inflammatory joint diseases. Arthritis Rheum. 1998;41:122129.
33. Amin AR, Attur M, Pate!, RN, et al. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage: influence of nitric oxide. / Clin Invest. 1997;99:1231 -1237.
34. Hay C, de Belleroche J. Carrageenan-induced hyperalgesia is associated with increased cyclo-oxygenase-2 expression in spinal cord. Neuroreport. 1997:8:1249-1251.
35. Dirig DM, Isakson PC, Yaksh TL. Effect of COX-1 and COX-2 inhibition on induction and maintenance of carrageenan-evoked thermal hyperalgesia in rats. J Pharmacol E.xp Ther. 1998; 285:1031-1038.
36. Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain. 1983; 17:197-210.
37. Barrier CH, Hirschowitz BI. Controversies in the detection and management of nonsteroidal antiinflammatory drug-induced side effects of the upper gastrointestinal tract. Arthritis Rheum. 1989; 32:926-932.
38. Scholes D, Stergachis A, Penna PM, Normand EH, Hansten PD. Nonsteroidal antiinflammatory drug discontinuation in patients with osteoarthritis. JRheumatol. 1995:22:708-712.
39. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis, part II: osteoarthritis of the knee. Arthritis Rheum. 1995;38:1541-1546.
40. Deippe P. Towards effective therapy for osteoarthritis. Rheumatol Eur. 1995;24:118-120.
41. Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI. Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N EnglJ Med. 1991;325:87-91.
42. Parr G, Darekar B, Fletcher A, Bulpitt CJ. Joint pain and quality of life: results of a randomised trial. Br J Clin Pharmacol. 1989;27: 235-242.
43. Doyle DV, Dieppe PA, Scott J, Huskisson EC. An articular index for the assessment of osteoarthritis. Ann Rheum Dis. 1981;40:75-78.
44. Roth SH. NSAID gastropathy: a new understanding. Arch Intern Med. 1996; 156:1623-1628.
45. Huang J, Hunt RH. A clinician's view of strategies for preventing NSAID-induced gastrointestinal ulcers. Inflammopharmacology. 1996:4:17-30.